Entinostat Helps Thwart Immunotherapy Resistance.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2019-048
Abstract: Findings from the ENCORE-601 trial's melanoma cohort show that the experimental HDAC inhibitor entinostat is well tolerated and, together with pembrolizumab, induces durable responses in patients whose disease has progressed on PD-1 blockade alone. read more here.
Keywords: entinostat helps; immunotherapy resistance; thwart immunotherapy; helps thwart ... See more keywords